Inositol — Expert Claims
Extracted from publicly available podcast transcripts and videos. Each claim is attributed and sourced.
Claims are extracted using AI (Claude) from publicly available transcripts and manually reviewed. Extraction confidence (high / medium / low) indicates accuracy of capture. Each claim is compared against PubMed research.
3 expert mentions
"Inositol is interesting because there's a dose-dependent effect. There's data showing that 12 to 18 grams — which is a very large amount — can reduce anxiety and panic attacks, and there's been a direct comparison to fluvoxamine. But there's also some data around 900 milligrams before sleep that people find helpful for sleep. Very different doses, very different contexts."
Myo-inositol taken at high doses (12-18g/day) has evidence for reducing anxiety and panic, while a lower dose around 900mg taken before sleep may support sleep quality — the effects are meaningfully dose-dependent.
The 12-18g/day for anxiety and panic is supported by a small double-blind crossover RCT (Palatnik et al.), though the evidence base is limited in size. The 900mg for sleep is a much lower-evidence claim — some users report benefit, but clinical trials specifically at this dose for sleep are limited. Huberman's characterization of dose-dependency is accurate and reflects the available literature honestly.
"There's actually been clinical research on inositol for OCD and panic disorder going back to the 1990s. The doses used were very high — around 18 grams a day — and in some studies it performed comparably to SSRIs for panic. I want to be careful here though: these were small studies, and this is not a replacement for evidence-based psychiatric treatment."
Inositol has been studied for OCD and panic disorder at doses of 12-18g/day with modest evidence. It may be a reasonable consideration for patients who cannot tolerate SSRIs, though the evidence base is small and replication is needed.
Marks accurately characterizes the inositol-OCD/panic literature. A double-blind crossover RCT by Palatnik et al. did show panic attack reduction at 18g/day versus fluvoxamine. However, the OCD evidence is weaker and less consistent, and the overall evidence base is small (few trials, small n). Her caution about not replacing standard psychiatric treatment is clinically appropriate.
"For women with PCOS, myo-inositol has some of the best evidence of any supplement for improving insulin sensitivity and restoring hormonal balance. The ratio matters — the physiological ratio of myo to d-chiro inositol in the ovary is roughly 40 to 1, and formulations that respect that ratio appear to perform better."
Myo-inositol is one of the better-supported supplements for insulin sensitivity and hormonal regulation in PCOS, with the myo to d-chiro-inositol ratio of 40:1 appearing to be physiologically relevant.
Attia's characterization is well-aligned with the available literature. Multiple RCTs and the Unfer et al. systematic review support myo-inositol for improving HOMA-IR, LH/FSH ratios, and menstrual regularity in PCOS. The 40:1 myo:d-chiro-inositol ratio reflects published pharmacological findings on ovarian tissue physiology. This represents the strongest evidence base for inositol supplementation across any indication.